ClinicalTrials.gg
CompletedNCT07301333Updated Sep 10, 2026

A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects

A Phase 1 interventional study of HRS-6257 and placebo in Pain, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Pain · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
9th of 15
80 · median 96
Started
2025
the only one that year
Phase 1
7 of 15
none open now
Registered
14th of 15
by date

Among the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd., this one is the 9th largest by enrollment, is the only one that started in 2025, is one of 7 in phase 1, and was the 14th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Pain, anywhere →

Where they have run

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy volunteers.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged between 18 and 55 years old (based on the time of signing the form), both males and females are eligible.
  2. The body weight of males ≥ 50 kg, and that of females ≥ 45 kg, and (BMI): 19 - 28 kg/m².
  3. Female subjects must be non-pregnant or non-;
  4. Subjects must understand the study procedures and methods, voluntarily participate in this study and sign the ICF in person.

Exclusion criteria

Exclusion Criteria:

  1. History of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological disease;
  2. Known or suspected to trial product(s) or related products;
  3. 12-lead demonstrating >450 msec or history or risk factors for QT prolongation;
  4. Blood donation of more than 200 mL within the last 6 months
  5. Use of prescription or nonprescription drugs and dietary and herbal supplements within 14 days or 7 half-lives;
  6. Positive screening tests for or C, , alcohol, drugs of abuse.
  7. Previous administration with an product (drug or vaccine) within 3 months;
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    HRS-6257 group

    Drug: HRS-6257

  • Placebo comparator
    placebo group

    Drug: placebo

Interventions

  • DrugHRS-6257

    HRS-6257

  • Drugplacebo

    placebo

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events

    Time frame: from ICF signing date to Day 14 or Day 21 or Day 27

Secondary outcomes

  1. AUC of HRS-6257

    Time frame: 0 hour to 72 hour after administration

  2. Cmax of HRS-6257

    Time frame: 0 hour to 72 hour after administration

  3. Tmax of HRS-6257

    Time frame: 0 hour to 72 hour after administration

  4. t1/2 of HRS-6257

    Time frame: 0 hour to 72 hour after administration

  5. CL/F of HRS-6257

    Time frame: 0 hour to 72 hour after administration

  6. Vz/F of HRS-6257

    Time frame: 0 hour to 72 hour after administration

  7. Pain tolerance time for the Cold Pain Test

    Time frame: Day 1 to Day 1 or Day 14

  8. Number of Participants With Clinically Meaningful Findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses

    Time frame: from ICF signing date to Day 14

07

Study locations

1 site
  • Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Jun 2026, 5 months.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 5 months is above that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 24, 2025
StartActual
Dec 30, 2025
Primary completionActual
Jun 16, 2026
CompletionActual
Jun 16, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07301333
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Dec 30, 2025
Primary completion
Jun 16, 2026
Completion
Jun 16, 2026
Last update
Sep 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion